Literatur
- 1
Findler G, Lavy S.
Transient hemiparesis; A rare manifestation of diphenylhydantoin toxicity.
J Neurosurg.
1979;
50
685-687
- 2
Sandyk R.
Transient hemiparesis - a rare complication of phenytoin toxicity.
Postgraduate Medical Journal.
1983;
59
601-602
- 3
Stephen L J, Maxwell J E, Brodie M J.
Transient hemiparesis with topiramate.
BMJ.
1999;
318
845
- 4
Bono A, Beghi E, Bogliun G. et al .
Antiepileptic drugs and peripheral nerve function: a multicenter screening investigation
of 141 patients with chronic treatment.
Epilepsia.
1993;
34
323-331
- 5
Geraldini C, Faeda M T, Sideri G.
Anticonvulsant therapy and its possible consequences on peripheral nervous system:
a neurographic study.
Epilepsia.
1984;
25
502-505
- 6
Dobkin B H.
Reversible subacute peripheral neuropathy induced by phenytoin.
Arch Neurol.
1977;
34
189-190
- 7
Yoshikawa H, Abe T, Oda Y.
Extremely acute phenytoin-induced peripheral neuropathy.
Epilepsia.
1999;
40
528-529
- 8
Ng K, Silbert P L, Edis R H.
Complete external ophthalmoplegia and asterixis with carbamazepine toxicity.
Aust N Z J Med.
1991;
21
886-887
- 9
Noda S, Umezaki H.
Carbamazepine-induced ophthalmoplegia.
Neurology.
1982;
32
1320
- 10
Spector R H, Davidoff R A, Schwartzman R J.
Phenytoin-induced ophthalmoplegia.
Neurology.
1976;
26
1031-1034
- 11
Crooks R, Mitchell T, Thom M.
Patterns of cerebellar atrophy in patients with chronic epilepsy: a quantitative neuropathological
study.
Epilepsy Research.
2000;
41
63-73
- 12
Luef G, Burtscher J, Kremser C. et al .
Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin
overdosages.
European Neurology.
1996;
36
273-277
- 13
Ney G C, Lantos G, Barr W B, Schaul N.
Cerebellar atrophy in patients with long-term phenytoin exposure and epilepsy.
Archives of Neurology.
1994;
51
767-771
- 14
Leppik I E, Gram L, Deaton R. et al .
Safety of tiagabine: summary of 53 trials.
Epilepsy Research.
1999;
33
235-246
- 15
Karas B J, Wilder B J, Hammond E J. et al .
Treatment of valproate tremors.
Neurology.
1983;
33
1380-1382
- 16 Fisher R S, Kerigan J F.
Vigabatrin Toxicity. In: Levy RH, Mattson RH, Meldum BS (eds) Antiepileptic Drugs. New York; Raven Press
1995: 985
- 17
Harrison M B, Lyons G R, Landow E R.
Phenytoin and dyskinesias: a report of two cases and review of the literature.
Movement Disorders.
1993;
8
19-27
- 18
van der Zwan A JR.
Transient Parkinson syndrome and tremor caused by the use of sodium valproate.
Ned Tijdschr Geneeskd.
1989;
133
1230-1232
- 19
Alvarez-Gomez M J, Vaamonde J, Narbona J. et al .
Parkinsonian syndrom in childhood after sodium valproat administration.
Clinical Neuropharmacology.
1993;
16
451-455
- 20
Onofrj M, Thomas A, Paci C.
Reversible parkinsonism induced by prolonged treatment with valproate.
J Neurol.
1998;
245
794-796
- 21
Armon C, Shin C, Miller P. et al .
Reversible parkinsonism and cognitive impairment with chronic valproate use.
Neurology.
1996;
47
626-635
- 22
Kurlan R, Kersun J, Behr J. et al .
Carbamazepine-induced tics.
Clinical Neuropharmacology.
1989;
12
298-302
- 23
Neglia J P, Glazen D G, Zion T E.
Tics and vocalizations in children treated with carbamazepine.
Pediatrics.
1984;
73
841-844
- 24
Robertson P L, Garofalo E A, Silverstein F S. et al .
Carbamazepine-induced tics.
Epilepsia.
1993;
34
965-968
- 25
Lombroso C T.
Lamotrigine-induced tourettism.
Neurology.
1999;
52
1191-1194
- 26
Menezes de Sotero A, Rho J, Murphy P. et al .
Lamotrigine-induced tic disorders: report of five pediatric cases.
Epilepsia.
2000;
41
862-867
- 27
Guerrini R, Belmonte A, Parmeggiani L. et al .
Myoclonic status epilepticus following high-dosage lamotrigine therapy.
Brain and Development.
1999;
21
420-424
- 28
Jacob P C, Chand R P, Omeima E.
Asterixis induced by gabapentin.
Clinical Neuropharmacology.
2000;
23
53
- 29
Rittmannsberger H, Leblhuber F.
Asterixis induced by carbamazepine therapy.
Biol Psychiatry.
1992;
32
364-368
- 30
Bodensteiner J B, Morris H H, Golden G S.
Asterixis associated with sodium valproate.
Neurology.
1981;
31
186-190
- 31
Duarte J, Sempere A P, Cabezas M C. et al .
Postural myoclonus induced by phenytoin.
Clinical Neuropharmacology.
1996;
19
536-538
- 32
Janszky J, Rásonyi G, Halász P. et al .
Disabling erratic myoclonus during lamotrigine therapy with high serum level - report
of two cases.
Clinical Neuropharmacology.
2000;
23
86-89
- 33
Marciani M G, Maschio M, Spannedda F. et al .
Development of Myoclonus in patients with partial epilepsy during treatment with vigabatrin;
an electroencephalographic study.
Acta Neurol Scand.
1995;
91
1-5
- 34
Asconape J, Diedrich A, DeallaBadia J.
Myoclonus associated with the use of gabapentin.
Epilepsia.
2000;
41
479-481
- 35
Evidente V G, Adler C H, Caviness J N. et al .
Effective treatment of orthostatic tremor.
Movement Disorders.
1998;
13
829-831
- 36
Onofrj M, Thomas A, Paci C. et al .
Gabapentin in orthostatic tremor: results of a double-blind cross-over with placebo
in four patients.
Neurology.
1998;
51
880-882
- 37
Ondo W, Hunter C, Vuong K D. et al .
Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled
trial.
Movement Disorders.
2000;
15
678-682
- 38
Pahwa R, Lyons K, Hubble J P. et al .
Double-blind controlled trial in essential tremor.
Movement Disorders.
1998;
13
465-467
- 39
Adler C H.
Treatment of restless legs syndrome with gabapentin.
Clinical Neuropharmacology.
1997;
20
148-151
- 40
Olson W L, Gruenthal M, Mueller M E. et al .
Gabapentin for parkinsonism: a double-blind, placebo-controlled, cross-over trial.
Am J Med.
1997;
102
60-66
- 41
Connor G S.
Topiramate as a novel treatment for essential tremor.
Movement Disorders.
1999;
14
908
- 42
Gálvez-Jimenéz N, Hargreave R N.
Topiramate and essential tremor.
Annals of Neurology.
2000;
47
837-838
- 43
Prevett M C, Brown P, Duncan J S.
Improvement of stiff-man syndrome with vigabatrin.
Neurology.
1997;
48
1133-1134
- 44
Vermeij F H, van Doorn P A, Busch H F.
Improvement of stiff-man syndrome with vigabatrin.
Lancet.
1996;
348
612
- 45
Shinotoh H, Vingerhoets F J, Lee C S. et al .
Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled,
cross-over study.
Neurology.
1997;
48
1282-1285
- 46
Zipp F, Burklin F, Stecker K. et al .
Lamotrigine in Parkinson's disease - a double-blind study.
J Neural Transm Park Dis Dement Sect.
1995;
10
199-206
- 47 Miller L G, Jankovic J.
Drug-induced dyskinesias: an overview. In: Joseph A, Young R (eds) Movement Disorders in Neurology and Neuropsychiatry. Oxford;
Blackwell 1999: 5-30
- 48
Sandyk R.
Total external ophthalmoplegia induced by phenytoin. A case report.
S Afr Med J.
1984;
65
141-142
Pascal Grosse
Neurologische Klinik und Poliklinik · Charité · Campus Virchow-Klinikum
Augustenburger Platz 1
13353 Berlin
